Terrence Higgins Trust uses cookies to improve your experience of our websites. For more information or to change the use of cookies, please click here.

Accept and Close

Stribild (elvitegravir + emtricitabine + tenofovir disoproxil + cobicistat)


Generic name: Stribild is a combination of the drugs elvitegravir, emtricitabine, tenofovir disproxil and a boosting agent, cobicistat.

Brand names: Stribild

Class: Complete combination tablets


Very common (affecting at least 1 in 10 people): Diarrhoea, vomiting, nausea, weakness, headache, dizziness, rash, decreased blood levels of phosphate, increased creatine kinase in the blood that can result in muscle pain and weakness.

Common (affecting 1 to 10 in every 100 people): Decreased appetite, insomnia (difficulty sleeping), abnormal dreams, pain, stomach pain, indigestion, bloating, flatulence, tiredness, low white blood cell count, increased sugar, fatty acids (triglycerides) or bilirubin, liver problems, pancreas problems, rashes – which can be caused by an allergic reaction, other allergic reactions, constipation, increased creatinine levels in the blood.

Uncommon (affecting up to 1 in every 100 people): Suicidal thoughts (in people who have had mental health problems or depression previously), depression, kidney problems (leading to back pain), kidney tubule cell damage, swelling of the lips, tongue or throat, abdominal pain caused by pancreatitis, muscle pain or weakness, muscle breakdown, anaemia, changes to urine, reduced amounts of potassium in the blood.


Tablet combines 200mg of emtricitabine, 245mg of tenofovir disoproxil and 150mg of elvitegravir, along with 150mg cobicistat. Cobicistat is a booster drug – it boosts the effect of elvitegravir.

Take one tablet, once a day.


Take with food.

*Last reviewed on 19/12/2016 Next review: 19/12/2019

Any questions? Email feedback@tht.org.uk Information included on this website was correct at the time of publication.

Data and image supplied by NAM.

Further information on this drug from NAM